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Wild-Type Monomeric -Synuclein Can Impair Vesicle
Endocytosis and Synaptic Fidelity via Tubulin
Polymerization at the Calyx of Held
XKohgaku Eguchi,1 Zacharie Taoufiq,1 XOliver Thorn-Seshold,2 XDirk Trauner,2 XMasato Hasegawa,3
and XTomoyuki Takahashi1
1Cellular and Molecular Synaptic Function Unit, Okinawa Institute of Science and Technology Graduate University, Okinawa 904-0495, Japan, 2Department
of Chemistry and Pharmacy and Centre for Integrated Protein Science, Ludwig-Maximilians-University Munich, 81377 Munich, Germany, and
3Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, Tokyo 156-8506, Japan
-Synuclein isapresynapticprotein the functionofwhichhasyet tobe identified,but itsneuronalcontent increases inpatientsof synucleinopa-
thies including Parkinson’s disease. Chronic overexpression of-synuclein reportedly expresses various phenotypes of synaptic dysfunction,
but the primary target of its toxicity has not been determined. To investigate this, we acutely loaded human recombinant -synuclein or its
pathological mutants in theirmonomeric forms into the calyces of Held presynaptic terminals in slices from auditorilymature and immature
rats of either sex. Membrane capacitancemeasurements revealed significant and specific inhibitory effects ofWTmonomeric-synuclein on
vesicle endocytosis throughout development. However, the -synuclein A53T mutant affected vesicle endocytosis only at immature calyces,
whereastheA30Pmutanthadnoeffect throughout.Theendocytic impairmentbyWT-synucleinwasrescuedbyintraterminalcoloadingofthe
microtubule (MT) polymerization blocker nocodazole. Furthermore, it was reversibly rescued by presynaptically loaded photostatin-1, a pho-
toswitcheable inhibitorofMTpolymerization, ina light-wavelength-dependentmanner. Incontrast, endocytic inhibitionbytheA53Tmutantat
immature calyces was not rescued by nocodazole. Functionally, presynaptically loadedWT-synuclein had no effect on basal synaptic trans-
mission evoked at a low frequency, but significantly attenuated exocytosis and impaired the fidelity of neurotransmission during prolonged
high-frequencystimulation.Weconclude thatmonomericWT-synucleinprimarily inhibitsvesicleendocytosisviaMToverassembly, thereby
impairing high-frequency neurotransmission.
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Introduction
Synucleins were originally cloned from Torpedo electric lobe,
where they localize in cell nuclei and axon terminals (Maroteaux
et al., 1988). The  isoform of synuclein, NACP, is enriched in
mammalian presynaptic terminals (Jakes et al., 1994; Murphy et
al., 2000).-Synuclein interacts with a variety of proteins (Chung
et al., 2017), including calmodulin (Zhou et al., 2004), actin
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Significance Statement
Abnormal -synuclein abundance is associated with synucleinopathies including Parkinson’s disease, but neither the primary
target of-synuclein toxicity nor its mechanism is identified. Here, we loadedmonomeric-synuclein directly into mammalian
glutamatergic nerve terminals and found that it primarily inhibits vesicle endocytosis and subsequently impairs exocytosis and
neurotransmission fidelity during prolonged high-frequency stimulation. Such-synuclein toxicity could be rescued by blocking
microtubule polymerization, suggesting that microtubule overassembly underlies the toxicity of acutely elevated -synuclein in
the nerve terminal.
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(Jensen et al., 1999; Sousa et al., 2009), tubulin (Alim et al., 2002;
Zhou et al., 2004), tau protein (Jensen et al., 1999; Zhou et al.,
2004), septin 4 (Ihara et al., 2007), ubiquitin (Zhou et al., 2004),
phospholipids (Sto¨ckl et al., 2008), andATP synthase (Ludtmann
et al., 2016), but its functional role has yet to be established.
In synucleinopathies including Parkinson’s disease (PD), ag-
gregates of -synuclein are found in neurons as Lewy bodies
(Spillantini et al., 1998) initially in axon terminals (Marui et al.,
2002). Missense mutations in the N-terminal -helix region,
such as A30P and A53T (Polymeropoulos et al., 1997; Kruger et
al., 1998), andmultiplication of the-synuclein gene SNCA (Sin-
gleton et al., 2003; Iba´n˜ez et al., 2004) are thought to underlie PD.
In fact, -synuclein is doubly expressed in SNCA triplication
(Singleton et al., 2003; Farrer et al., 2004) and PD progression is
reportedly proportional to the SNCA gene dosage (Chartier-
Harlin et al., 2004). In the early stage of sporadic PD,-synuclein
is accumulated in brainstem presynaptic terminals and is subse-
quently propagated to upper CNS synapses (Braak et al., 2003),
possibly by a prion-like protein-misfolding mechanism (Bendor
et al., 2013).
Experimental overexpression of -synuclein disrupts micro-
tubule (MT)-dependent vesicle trafficking in cultured cells (Lee
et al., 2006) and reduces dopamine release from secretory cells
(Larsen et al., 2006; Choi et al., 2013) or from dopaminergic
neurons in vivo (Lundblad et al., 2012). -Synuclein overexpres-
sion also reduces glutamate release and the number of recycling
vesicles in cultured hippocampal neurons (Nemani et al., 2010).
In contrast,-synuclein overexpression reportedly promotes vesicle
endocytosis in neuronal cell lines (Ben Gedalya et al., 2009) and
causes synaptic potentiation in cultured hippocampal neurons (Liu
et al., 2004). Suchdiverse phenotypes of-synuclein overexpression
may include secondary effects, such as those mediated by -
synuclein binding partners. Therefore, we searched for a primary
target of elevated -synuclein toxicity by acutely loading it directly
into glutamatergic presynaptic terminals, the calyces of Held, in
slices from rat brainstem. Our results indicate thatWTmonomeric
-synuclein inhibits vesicle endocytosis, thereby impairing the fidel-
ity of high-frequency neurotransmission. Our results also suggest a
mechanism of excess MT assembly underlying the toxic effect of
-synuclein.
Materials andMethods
Experiments. All experiments were performed in accordance with guide-
lines of the Physiological Society of Japan and animal experiment regu-
lations at the Okinawa Institute of Science and Technology Graduate
University.
Preparation. After decapitation under halothane anesthesia, brains-
temswere isolated fromWistar rats of either sex at two different ages, one
before at postnatal days 7 (P7)–P9 and the other after (P13–P14) the
hearing onset. Transverse slices of the brainstem containing the medial
nucleus of the trapezoid body (MNTB)were cut at a thickness of 175–200
m using a microtome (VT1200S; Leica). Before recordings, slices were
incubated for 1 h at 36–37°C in artificial CSF (aCSF) containing the
following (in mM): 125 NaCl, 2.5 KCl, 1 MgCl2, 2 CaCl2, 10 glucose, 3
myo-inositol, 2 sodium pyruvate, 0.5 sodium ascorbate, 1.25 NaH2PO4,
and 26 NaHCO3 at 310–315 mOsm, pH 7.4, saturated with 95% O2 and
5% CO2. WT human recombinant -synuclein was subcloned into
pRK172 and expressed in E. coli BL21(DE3) (Masuda et al., 2006); mo-
nomeric WT -synuclein was purified as described by Oikawa et al.
(2016). Monomeric WT -synuclein (tagged with histidine) was also
obtained from Sigma-Aldrich. Monomeric -synuclein mutants (A30P
and A53T) were also purchased from Sigma-Aldrich. Lyophilized pow-
ders were dissolved at 36M inH2O and desalted and concentrated using
centrifugal filter units (Amicon Ultra-2 ml 3K; Millipore). After adjust-
ing the concentration to 360 M, they were diluted with pipette internal
solution to different concentrations (0.7–22 M). Nocodazole (Calbio-
chem) and photostatin-1 (see below for details) were dissolved in inter-
nal solution containing 0.1% DMSO and infused into presynaptic
terminals at a final concentration of 10 M.
Electrophysiology. Calyces of Held presynaptic terminals and postsyn-
aptic MNTB principal cells were identified visually with a 40 water-
immersion objective attached to an upright microscope (BX51WI;
Olympus). Data were acquired at a sampling rate of 50 kHz using an
EPC-10 USB double patch-clamp amplifier controlled by PatchMaster
software (HEKAElektroniks, RRID:SCR_000034) after online filtering at
5 kHz. Experiments were performed at room temperature (26–27°C).
Resistances of patch electrodes were 4–8 and 1–3 M for presynaptic
and postsynaptic recording, respectively. Proteins and drugs were in-
fused from whole-cell pipettes into calyceal terminals by diffusion. For
whole-cell voltage-clamp recordings, presynaptic and postsynaptic series
resistances were 8–14 and 4–7M and compensated by up to 60% for a
final value of 7 and 3 M, respectively. Care was taken to keep the
presynaptic access resistance before compensation14 M. With these
access resistances (8–14M), -synuclein (20 kDa) diffuses into a calyx
terminal having a volume of 960 m3 (Vasileva et al., 2013) with a time
constant of 11–20 s after whole-cell rupture (Pusch and Neher, 1988).
Data were obtained 4–30 min after break-in.
For recording evoked EPSCs, simultaneous presynaptic and postsyn-
apticwhole-cell recordingsweremade froma calyceal nerve terminal and
postsynaptic cell. Throughout the experiments, presynaptic recordings
were made in current-clamp mode, whereas postsynaptic recordings
were made in voltage-clamp mode at a holding potential of 70 mV.
Pipette solution for recording of presynaptic action potentials (APs) con-
tained the following (in mM): 110 K-gluconate, 10 L-glutamate, 30 KCl,
10 HEPES, 0.5 EGTA, 12 Na2-phosphocreatine, 3 MgATP, 1MgCl2, and
0.3 Na2GTP at 315 mOsm, pH 7.3, adjusted with KOH. Solution for
postsynaptic recording contained the following (in mM): 110 CsF, 30
CsCl, 10 HEPES, 5 EGTA, 1 MgCl2, and 5 QX314-Cl at 300 mOsm, pH
7.3, adjusted with CsOH. EPSCs were evoked by depolarizing current
injection (0.5–1 nA, 1 ms) into the presynaptic terminal via a recording
glass electrode in the presence of bicuculline methiodide (10 M) and
strychnine hydrochloride (0.5 M).
For recording postsynaptic APs, simultaneous presynaptic and post-
synaptic whole-cell recordings were made from calyceal terminals and
postsynaptic MNTB principal neurons, both in current-clamp mode, in
the presence of bicuculline methiodide (10 M) and strychnine hydro-
chloride (0.5 M). Pipette solution for postsynaptic AP recording con-
tained the following (in mM): 120 K-gluconate, 30 KCl, 5 EGTA, 12
Na2-phosphocreatine, 3MgATP, 1 L-arginine, 1MgCl2, and 0.3 Na2GTP
at 315 mOsm, pH 7.3, adjusted with KOH. Presynaptic APs were elicited
by a square pulse current injection into calyces in current-clamp mode
via recording glass electrodes filled with K-gluconate-based internal so-
lution (as above).
For membrane capacitance measurements, calyceal terminals were
voltage clamped at a holding potential of 80 mV and a sinusoidal
voltage command with a peak-to-peak voltage of 60 mVwas applied at 1
kHz (Sun and Wu, 2001; Yamashita et al., 2005). To isolate presynaptic
voltage-gated Ca2 currents (ICa), the aCSF contained 10 mM tetraeth-
ylammonium chloride, 0.5 mM 4-aminopyridine, 1 M tetrodotoxin, 10
M bicuculline methiodide, and 0.5M strychnine hydrochloride. Intra-
cellular solution for presynaptic terminals contained the following (in
mM): 125 Cs-methanesulfonate, 30 CsCl, 10 HEPES, 0.5 EGTA, 12 Na2-
phosphocreatine, 3 MgATP, 1 MgCl2, and 0.3 Na2GTP at 315–320
mOsm, pH 7.3, adjusted with CsOH. Tips of recording pipettes were
coated with dental wax to reduce stray capacitance (4–6 pF). Single-
pulse step depolarization (to 10 mV, 20 ms) was used to induce pre-
synaptic ICa unless otherwise noted. Membrane capacitance (Cm)
changes within 450 ms of square-pulse stimulation were excluded from
analysis to avoid contamination with conductance-dependent capaci-
tance artifacts. Rapid endocytosis was elicited by a 20 ms depolarizing
pulse train (20 times, 1Hz) and the endocytic ratewas estimated from the
slope fit with a linear regression line toCmdecay 0.45–1 s after each pulse.
To avoid the influence of capacitance drift on baseline, we discarded data
when the baseline drift measured 0–10 s before stimulation was5 fF/s.
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When the capacitance baseline drift was 1–5 fF/s, for the baseline correc-
tion, we subtracted a linear regression line of the baseline from the data.
Native gel electrophoresis. -Synuclein proteins (3.6 M) were resus-
pended in pipette internal solution before loading onto a Novex native
gel (3–12% gradient; Invitrogen). Protein size markers (Native Mark;
Invitrogen) were used as a standard and electrophoresis was performed
according to the manufacturer’s instructions. After the protein transfer,
the nitrocellulosemembranewas labeled using anti--synuclein primary
antibody (SC-7011-R, RRID:AB_2192953; Santa Cruz Biotechnology)
and secondary goat-anti-rabbit IgG-HRP (RRID:AB_11125142; Bio-Rad
Laboratory). Bands were visualized using the Molecular Imager Chemi-
Doc system (Bio-Rad).
Photostatin. Photo-switchable microtubule inhibitor photostatin-1
(PST-1, 46 mM stock solution in DMSO; Borowiak et al., 2015) was
diluted to 10 mM stock DMSO solution. Just before the experiments,
stock solution was diluted to 10 M with pipette internal solution (0.1%
in final DMSO concentration) and sonicated to avoid precipitation. To
minimize adhesion of PST-1 to plastic surfaces, glass syringes and vials
were used and a metal spinal needle (TOP) was used for loading internal
solution into patch pipettes. PST-1 loaded in presynaptic terminals was
activated by illumination at 390 nm and inactivated at 510 nm supplied
to slices through a 40 water-immersion objective lens with a Xenon
lamp (70W, 100 ms pulses every 2 s) under the control of a shutter
(Lambda 10-B; Sutter Instrument). When the shutter was opened, the
whole area under the objective lens was illuminated. Cells illuminated at
390 nm showed inhibited exocytic capacitance change. This effect was
prevented by replacing 20 mM methanesulfonate with equimolar gluta-
thione in the presynaptic pipette solution (Hori and Takahashi, 2012).
Data analysis. Data were analyzed using IGOR Pro 6 (RRID:
SCR_000325; WaveMatrics) with Patcher’s Power Tools (RRID:
SCR_001950; Max-Planck-Institute), Microsoft Excel 2011/2016 for
Mac, and StatPlus:mac (RRID:SCR_014635; AnalystSoft). Sample Cm
records are shown as average values for each 50 data points (for 50 ms)
plotted every 50 ms (for shorter time scales) or every 500 ms (for longer
time scales). All values are given asmean SEM. For statistical tests, p
0.05 (indicated by single asterisks) was taken as significant in Student’s t
test, paired t test, one-way ANOVAwith the Tukey–Kramer post hoc test,
or two-way ANOVA with the Scheffe post hoc test.
Results
WT-synuclein inhibits vesicle endocytosis, but the A30P
and A53Tmutants do not
It has been reported recently that WT -synuclein and its A53T
mutant inhibit endocytosis of synaptic vesicles at the calyx of
Held of immature rodents before hearing onset (P7–P10; Xu et
al., 2016). Because endocytic properties at the calyx of Held un-
dergo significant changes after hearing (Renden and von Gers-
dorff, 2007; Yamashita et al., 2010; Eguchi et al., 2012), we
revisited this issue using posthearing rats (P13–P14). In contrast
to the report by Xu et al. (2016) showing oligomeric bands for the
commercially available -synuclein or its mutants, our WT
-synuclein, purified or purchased (His tag; Sigma-Aldrich), as
well as -synuclein mutants A30P and A53T (Sigma-Aldrich),
showed single bands in native PAGE gel-electrophoresis (Fig.
1A). Because -synuclein purified from brain tissue is predomi-
nantly monomeric (Burre´ et al., 2013) and it takes several days to
convert it to oligomer (Krishnan et al., 2003; Kim et al., 2008;
Burre´ et al., 2013), it should remain monomeric in the terminal
within the time of our experiments. WT -synuclein monomer
(3.6 M) with or without His tag loaded into presynaptic termi-
nals via a recording pipette significantly inhibited endocytic ca-
pacitance change (Fig. 1B), prolonging its half decay time (T0.5)
by	2-fold without affecting presynaptic Ca2 current (QCa) or
exocytic capacitance change (
Cm) (Fig. 1B2). As reported in
prehearing immature calyces (Xu et al., 2016), the A30P mutant
(3.6 M) had no effect, but unlike that report, A53T also had no
effect at more mature calyces (Fig. 1B1,B2). The results were also
essentially the same at physiological temperature (35°C) except
that endocytic kineticswere faster (T0.5, 6.5 0.6 s in control,n
5; 12.1 2.0 s with-synuclein, n 6). The endocytic inhibitory
effect of WT synuclein was concentration dependent, approach-
ing amaximum at	3.6M (Fig. 1C; see also Xu et al., 2016).WT
-synuclein also inhibited fast endocytosis of subsecond time
constants that are known to accelerate during a train of 1 Hz
stimulation (Wu et al., 2005; Yamashita et al., 2010) by strongly
attenuating the maximal rate of endocytosis (Fig. 1D). Neither
the A30P nor A53T mutant attenuated this fast endocytosis (Fig.
1D). Therefore, WT -synuclein, but neither of these pathologi-
cal mutants, inhibited vesicle endocytosis at this auditory relay
synapse after hearing onset. Although neither WT nor mutant
-synuclein affected exocytosis evoked by a single pulse depolar-
ization (Fig. 1B), prolonged repetitive stimulation revealed, in
cumulative plots, a significant inhibition of exocytosis by WT
-synuclein, and enhancement of exocytosis by A30P mutant
(p 0.05; Fig. 1D).
Mechanism underlying the inhibitory effect of -synuclein on
vesicle endocytosis
Although the inhibitory effect of -synuclein on vesicle endocy-
tosis has been suggested (Boassa et al., 2013; Busch et al., 2014)
and demonstrated (Xu et al., 2016; Fig. 1), little is known about
the underlying mechanism. Because -synuclein binds to PIP2
(Sto¨ckl et al., 2008), which operates for accelerating endocytosis
(Eguchi et al., 2012; Taoufiq et al., 2013), we first tested whether
intraterminal PIP2 loading might rescue -synuclein-induced
endocytic inhibition. PIP2 (50 M) loaded with WT -synuclein
showed a tendency to rescue the inhibitory effect of -synuclein
on endocytosis, but the difference was statistically insignificant
(Fig. 2A, p 0.20). Because-synuclein can bind to actin (Jensen
et al., 1999; Sousa et al., 2009), we also tested whether the actin
depolymerizer latrunculin A might rescue -synuclein-induced
endocytic inhibition. As shown in Figure 2B, intraterminal
loading of latrunculin A (25 M) had no rescuing effect on
-synuclein-induced endocytic inhibition. Among various bind-
ing partners, -synuclein binds to tubulins (Alim et al., 2002;
Zhou et al., 2004) and reportedly polymerizes them into MTs in
vitro (Alim et al., 2004, but see Oikawa et al., 2016). It can also
bind to tau protein (Jensen et al., 1999; Zhou et al., 2004) and
promotes its phosphorylation (Jensen et al., 1999). We therefore
investigated whether pharmacological block of tubulin polymer-
ization might rescue the inhibitory effect of -synuclein on vesi-
cle endocytosis. We first tested nocodazole, which specifically
blocks MT assembly. Nocodazole loaded alone into presynaptic
terminals (10M) had no effect on presynapticmembrane capac-
itance change, but when coloaded with -synuclein, completely
rescued the inhibitory effect of -synuclein on vesicle endocyto-
sis (Fig. 2C). Likewise, nocodazole (10M) rescued the inhibitory
effect of -synuclein on the accelerating fast endocytosis during
the stimulus train and slow endocytosis thereafter (Fig. 2D).
Toconfirmthe specificityof thenocodazole inhibitionof tubulin
polymerization, we used the recently introduced photo-switchable
tubulin polymerization inhibitor PST-1 (Borowiak et al., 2015), a
colchicine derivative activated under short-wavelength light, but in-
activated under long-wavelength light. When PST-1 (10 M) was
loaded alone into the calyx of Held terminal, it had no effect on
exo–endocytic capacitance changes under both short-wavelength
(390nm)and long-wavelength (510nm) light (Fig. 2E).When itwas
coloadedwith-synuclein under 390 nm light,-synuclein no lon-
ger inhibited endocytosis, whereas switching the light wavelength to
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Figure 1. WT monomeric -synuclein inhibits slow and fast vesicle endocytosis at calyces of Held in slices from posthearing rats, but its mutants do not. A, Native PAGE (from left to right);
monomeric humanWT-synuclein (purified byM.H.), that obtained fromSigma-Aldrich (His tag), andmonomeric A30P andA53T-synucleinmutants fromSigma-Aldrich, all dissolved in pipette
solution. B1, Exo– endocytic Cm changes of calyceal presynaptic terminals evoked by ICa (induced by a 20 ms pulse stepping from80 mV to10 mV). Left, Intraterminal loading of monomeric
WT-synucleins (3.6M) from different sources similarly slowed endocytic Cm changes without affecting exocytic Cm changes or ICa (red and yellow traces superimposedwith control black traces,
each averaged from records in seven to eight terminals). Right, A30Por A53T-synucleinmutants (3.6M), loaded into presynaptic terminals, hadno significant effect (superimposedblue or green
traces, averaged from records in four to six terminals). B2, Bar graphs showing the effects of WT -synucleins, His tag WT -synuclein, and A30P and A53T mutants on the 50% decay time of
endocytic Cm (left), the magnitudes of exocytic Cm jump (middle), and presynaptic Ca
2 current charge (QCa, right). C, Intraterminal loading of-synuclein (His tag) at different concentrations
(0.7–22M) slowed vesicle endocytosis in a concentration-dependent manner. Top, Cm traces; data from six to seven calyces were averaged, normalized at the peak, and superimposed. Bottom,
Half endocytic decay timeatdifferent-synuclein concentrations (n6–7 for eachdatapoint). Asterisks indicatea significantdifference fromthe control (withno-synuclein).D, Top,Cmchanges
induced by 20 ms depolarizing pulses (arrows indicate stimulations) repeated at 1 Hz for 20 s at calyceal terminals loaded with-synuclein (His tag, red), A30P (blue), A53T mutant (green), or
without loading (black, control). Traces represent average Cm changes from four to seven calyces. Bottom left, Endocytic rate during the train (fF/s, ordinate) estimated from a linear regression line
fit to the Cmdecay0.45–1 s after eachpulse versus stimulusnumber (abscissa) in calyceal terminalswith-synuclein (red,n5), A30P (blue,n6), A53T (green,n4), orwithout them(control:
black, n 7). The endocytic Cm decay after each pulse (initial rate: 56.1 12 fF/s) became gradually faster and reached a maximal rate of 183 14 fF/s at around the 10
th pulse (mean value of
10 th–20 th events, n 7). -Synuclein decreased the maximal rate to 96.8 17 fF/s (n 5, p 0.05). Bottom center, Bar graphs indicating the maximal endocytic rate in the presence of
-synuclein, A30P, A53T mutants, or in their absence. Bottom right, Cumulative 
Cm during the 20 s train (ordinate) versus stimulus number (abscissa) in calyceal terminals loaded with WT
-synuclein (red, n 5), A30P (blue, n 6), A53T (green, n 4), or without loading (control, black, n 7). WT-synuclein significantly reduced the cumulative
Cm ( p 0.05 from 11
th
stimulus), whereas A30P mutant significantly increased the cumulative
Cm ( p 0.05 from sixth stimulus) compared with controls. A53T mutant had no effect.
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Figure 2. The tubulin depolymerizers nocodazole and photostatin-1 can rescue the inhibitory effects of-synuclein on vesicle endocytosis. A, B, Coloading of PIP2 (50M, n 5, red in A) or
latrunculinA (25M,n6, red inB) togetherwithWT-synuclein hadno significant rescuing effect (n.s. inA,p0.20) for the inhibitory effect of-synuclein on vesicle endocytosis. Yellow trace
inA indicates the endocytic inhibitory effect ofWT-synuclein for comparison. Bar graphs indicate endocytic 50%decay time, averaged fromdata in five to seven calyces. LatrunculinA loaded alone
in calyceal terminals had no effect on vesicle endocytosis (n 5, blue trace in B). C, Intraterminal loading of nocodazole (10M) together withWT-synuclein with (red) or without (orange) His
tag (3.6M) rescued the inhibitory effect of-synuclein on vesicle endocytosis inducedby a single 20mspulse. Nocodazole alone (blue trace) hadnoeffect. Bar graphs indicate endocytic 50%decay
time averaged from data in five to seven calyces.D, Nocodazole coloading (10M) rescued the inhibitory effects of-synuclein (His tag, 3.6M) on accelerating fast endocytosis induced by a train
of 20ms pulse at 1 Hz. Left, Traces of control (black), nocodazole alone (blue), andWT-synuclein coloadedwith nocodazole (red, superimposed). Center and right, Endocytic rates were similar in
control (black), nocodazole alone (blue), and -synuclein nocodazole (red), as shown in time plots and bar graphs (n 5–7). E, PST-1 reversibly rescued endocytic inhibitory effects of
-synuclein. Intraterminal loading of PST-1 (10M) alone had no effect under 390 nm (black trace) or 510 nm (green trace) illumination (left sample traces), but, when loaded with-synuclein
(His tag, 3.6M, right traces), rescued its inhibitory effect on vesicle endocytosis under 390 nm illumination (black trace), but not under 510 nm light (right sample traces). In sample traces,
Cm
amplitude was normalized at the peak to compare endocytic time courses. Time plots (middle panel) indicate endocytic 50% decay time under 390 or 510 nm illumination in the presence of PST-1
and-synuclein (filled circles) and PST-1 alone (open circles). In the presence of PST-1 and-synuclein, the endocytic rate was slowed when PST-1 was inactivated by 510 nm light, but became
faster when returned to 390 nm illumination. Right panel summarizes the mean half endocytic decay time from five terminals at three epochs in the time plot showing significant and reversible
rescue by PST-1 from-synuclein-induced endocytic inhibition under 390 nm illumination. Asterisks indicate a significant difference (*p 0.05).
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510 nm revealed its inhibitory effect on en-
docytosis.When the lightwas switchedback
to 390 nm, the endocytic inhibitory effect of
-synuclein was again cancelled. Therefore,
PST-1 reversibly rescued the inhibitory ef-
fect of -synuclein on vesicle endocytosis.
These pharmacological results using no-
codazole and PST-1 strongly suggest that
MT assembly is involved in the inhibitory
effect of-synuclein on vesicle endocytosis.
Inhibitory effect of A53Tmutants on
vesicle endocytosis in
prehearing animals
Because the -synuclein A53Tmutant in-
hibits vesicle endocytosis at calyces of
Held in prehearing rats (Xu et al., 2016),
but not in posthearing rats (Fig. 1B), we
reexamined the effect of A53T mutant on
endocytosis at calyces from prehearing
(P7–P9) rats (Fig. 3). As reported previ-
ously (Xu et al., 2016), bothWTandA53T
mutant -synucleins inhibited endocyto-
sis, whereas A30P mutant had no effect
(Fig. 3A). As in posthearing rats (Fig. 2C),
nocodazole (10 M) rescued the inhibi-
tory effect of WT -synuclein (Fig. 3B).
Like calyces in posthearing rats (Fig. 2C),
nocodazole alone had no effect on endo-
cytosis in prehearing rats (Fig. 3B,C).
However, unlike in posthearing rats, no-
codazole failed to rescue the endocytic
inhibitory effect of the A53Tmutant in pre-
hearing rat calyces (Fig. 3C), suggesting that
a distinct MT-independent mechanism
may underlie the endocytic inhibitory effect
of A53Tmutant in prehearing rodents.
Impact of endocytic inhibition by
-synuclein on neurotransmission
The inhibitory effect of a-synuclein on
vesicle endocytosis has been inferred from
expanded presynaptic membrane after its
overexpression or injection (Boassa et al.,
2013; Busch et al., 2014) and was shown
directly by Xu et al. (2016) and here (Fig.
1) at rodent calyces of Held. However,
it remains unexplained how a-synuclein
impairs neurotransmission. In simultane-
ous presynaptic and postsynaptic whole-
cell patch-clamp recordings at the calyx of
Held, we loadedWT-synuclein (3.6M)
into presynaptic terminals. -Synuclein
had no effect on basal glutamatergic neurotransmission; the
mean amplitude or shape of EPSCs evoked at 0.03 Hz remained
unchanged (Fig. 4A). We then tested its effect on high-frequency
neurotransmission. A train of 30 stimulations at 100 Hz induces
short-term depression (STD) of EPSC amplitude (Fig. 4B). Cu-
mulative EPSC amplitude during the train was unchanged by
-synuclein loading (p 0.91). The STD is followed by a recov-
ery with a biexponential time course (Fig. 4C), reflecting fast and
slow replenishment of synaptic vesicles to release sites (Wang and
Kaczmarek, 1998). In these experiments, at room temperature,
the overall recovery rate is twice as slow as that at physiological
temperature (Kushmerick et al., 2006). The slow recovery com-
ponent reflects the time course of vesicle endocytosis (Hosoi et
al., 2009), whereas the fast recovery is caused by Ca2-dependent
vesicle replenishment to release sites (Wang and Kaczmarek,
1998). -Synuclein selectively prolonged the slow component
without affecting the fast component of recovery (Fig. 4C). No-
codazole alone (10M) loaded into presynaptic terminals had no
effect on the recovery rate, but when coloaded with -synuclein
(3.6 M), canceled its inhibitory effect on the recovery rate
Figure 3. -Synuclein A53T mutant inhibits vesicle endocytosis at calyces of Held in prehearing rats in a MT-independent
manner. A, In rat calyces of Held from prehearing rats (P7–P9), bothWT-synuclein (His tag, 3.6M, n 5, red) and A53T (3.6
M, n 5, blue) inhibited endocytic capacitance change elicited by a 20 ms depolarizing pulse ( p 0.05), whereas the A30P
mutant (3.6M, n 5, green) had no effect ( p 0.42). Bar graphs indicatemean endocytic recovery (%) fromexocytic
Cm50 s
after stimulation. B, Endocytic inhibition by WT -synuclein (His tag) rescued by nocodazole (10M, n 4–5, no significant
difference between nocodazole alone andWT-synuclein nocodazole, p 0.89). C, Endocytic inhibition by the A53Tmutant
could not be rescued by nocodazole (10M, n 4–5, significant difference between nocodazole alone and A53T nocodazole,
p 0.05). Asterisks indicate a significant difference (*p 0.05).
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(Fig. 4D). Therefore, nocodazole rescued the inhibitory effect of
-synuclein on the slow replenishment of synaptic vesicles.
Finally, we tested the effects of -synuclein on the fidelity of
high-frequency neurotransmission by recording postsynaptic
APs (output) in response to presynaptic APs (input) elicited by
100 Hz stimulation (Eguchi et al., 2012). During a sustained 100
Hz stimulation, postsynaptic AP firings remained stable at least
for 30 s in controls, whereas at synapses loaded with -synuclein,
APs started to fail within	10 s after stimulation (Fig. 4E). Fifty
seconds after the sustained stimulation, synaptic fidelity, defined
as a ratio of postsynaptic APs relative to presynaptic APs per
second, dropped down to 	50% at synapses loaded with
-synuclein, but remained at 	75% in control (p  0.05 in
2-way ANOVA with Scheffe post hoc test, n  4–5). Therefore,
presynaptically loaded-synuclein significantly impaired fidelity
of high-frequency neurotransmission.
We next investigated whether the toxic effect of -synuclein
on high-frequency transmission can be rescued by nocodazole.
When nocodazole (10 M) was coloaded with -synuclein (3.6
M) into calyceal terminals, synaptic fidelity during 100Hz stim-
ulation remained similar to controls without -synuclein (Fig.
4E). Therefore, nocodazole rescued high-frequency neurotrans-
mission impaired by -synuclein.
Discussion
In the present study, we have shown that acute loading of WT
monomeric -synuclein into the calyx of Held presynaptic ter-
minals inhibits endocytosis of synaptic vesicles, whereas the
-synuclein mutants A30P and A53T had no such effect. Al-
though -synuclein mutants enhance -synuclein aggregation
(Kruger et al., 1998; Li et al., 2001), acute loading or overexpres-
sion of the A30P mutant has no inhibitory effect on exo–endo-
Figure 4. Toxic effects of WT-synuclein on high-frequency neurotransmission. A, W-synuclein (His tag) has no effect on basal transmission at 0.03 Hz. EPSCs (bottom traces) evoked by
presynaptic action potentials (top traces) at 0.03 Hz in the presence (red) or absence (black) ofWT-synuclein (3.6M, superimposed). In bar graphs, themean amplitude of EPSCs was 6.8 1.3
nA (n 6) and 6.1 1.4 nA (n 6) in the absence and presence of-synuclein, respectively ( p 0.72, Student’s t test). The decay time constant of EPSCswas 0.96 0.09ms (n 6) and 1.1
0.1 ms (n 6) in the presence and absence of-synuclein, respectively ( p 0.29). B, Left, EPSCs evoked by a train of 30 stimuli at 100 Hz in the presence (red) or absence (control, black) of
-synuclein (His tag, 3.6M) in calyceal terminals. Right, Cumulative amplitudes of EPSCs during a 100 Hz train with (red, n 6) or without (black, n 6) WT-synuclein. WT-synuclein had
no effect on cumulative amplitude of EPSCs ( p 0.91). C, Recovery of EPSCs from STD in the presence (red) and absence (black) of-synuclein (His tag, 3.6M) in calyceal terminals. The 100 Hz
stimulation was followed by test stimuli at different interstimulus intervals (0.02–20 s, protocol on the top panel). Sample traces in insets indicate EPSCs at different intervals after STD (superim-
posed). Right bar graphs indicate mean and SEMs of fast and slow recovery time constants () from five to six synapses showing a significant prolongation (*) by-synuclein of the slow recovery
time constant in double exponential fits (solid lines in timeplots); 6.20.8 s in control, 122 swith-synuclein. Therewasno significant difference in fast recovery time constants.D, Nocodazole
(10M) rescued the inhibitory effect of-synuclein (His tag) on recovery of EPSCs from STD (n 7). Recovery in the presence of-synuclein alone (Fig. 4B) is indicated by a dashed line. Loading
nocodazole alone (10M, blue, n 6) had a similar recovery time to control (black). Bar graphs in the right panel indicate no significant effect of-synuclein on the recovery time after STD in the
presence of nocodazole. E, Left panels show postsynaptic APs (output) in response to presynaptic APs (input) elicited at 100 Hz in the control (left) in the presence of -synuclein (middle) and
-synuclein nocodazole (right) at different time periods during sustained stimulation. Center panels indicate the inhibitory effect of-synuclein on synaptic fidelity (in output/input ratio; filled
red circles, n 4; left) comparedwith control (open black circles, n 5). Right panel shows rescuing effect of coloaded nocodazole (10M, right panel, open red circles, n 4). Nocodazole alone
(10M) had no effect (blue-filled circles, n 4). The dashed line indicates impaired synaptic fidelity by-synuclein for comparison.
Eguchi et al. •Wild-Type-Synuclein Impairs Synaptic Fidelity J. Neurosci., June 21, 2017 • 37(25):6043–6052 • 6049
cytosis or vesicle recycling (Nemani et al., 2010; Busch et al., 2014;
Xu et al., 2016). Nevertheless, at the calyx of Held, the A30P
mutant significantly augmented exocytosis after a train of 1 Hz
stimulation (Fig. 1D).Mechanisms underlying this effect of A30P
mutant remain to be investigated. TheA53Tmutant had a similar
effect to that of WT -synuclein in overexpression studies at
cultured hippocampal synapses (Nemani et al., 2010) and calyces
of Held (Xu et al., 2016). In addition, in acute loading experi-
ments, the A53T mutant inhibited endocytosis at prehearing rat
calyces of Held (Xu et al., 2016; Fig. 3A), but this effect disappeared
after hearing onset (Fig. 1A). At the calyx of Held, vesicle endocytic
mechanisms undergo substantial changes during the second
postnatal week, when rodents start to hear sound (Takahashi,
2015). For example, GTP-independent component disappears
and calmodulin/calcineurin-dependent endocytosis becomes
nonfunctional (Yamashita et al., 2010), whereas an activity/PKG-
dependent endocytic facilitationmechanism becomes functional
(Eguchi et al., 2012). Given that PD is associated with aged indi-
viduals, pathological significance of the endocytic inhibitory ef-
fect of -synuclein A53T mutant, observed only transiently in
immature animals (Xu et al., 2016), is unclear.
The -synuclein preparations used by Xu et al. (2016) for
intraterminal loading contained both monomers and oligomers.
In the brain, native -synuclein exists predominantly in amono-
meric state (Burre´ et al., 2013), possibly in equilibrium with its
oligomers (Bartes et al., 2011). When the -synuclein concentra-
tion increases, it can slowly aggregate into fibrils with a time
course of 20–60 h (Kim et al., 2008). It also takes several days
before purified monomeric -synuclein is converted to oligom-
ers (Krishnan et al., 2003; Burre´ et al., 2013). Furthermore, in
whole-cell recordings, soluble molecules in patch pipettes pre-
dominate in the presynaptic terminal cytosolic concentration
(Pusch and Neher, 1988). Therefore, under our experimental con-
ditions,WT-synuclein should remainmonomeric throughout the
experimental period. In previous loss-of-function studies, -
synuclein triple knock-out reduces mitochondrial ATP synthesis
(Ludtmann et al., 2016) and inhibits vesicle endocytosis (Vargas et
al., 2014), suggesting that -synuclein, together with -synuclein
and -synuclein, may normally support ATP supply that is indis-
pensable for vesicle endocytosis (Rangaraju et al., 2014). Despite the
fact that -synuclein is essential for vesicle endocytic function, its
abnormal upregulationmay induce toxic functions, likemanyother
indispensable molecules. A simple increase of -synuclein in cells
may be sufficient for its misfolding and transcellular propagation
(Bendor et al., 2013).
The inhibitory effect of -synuclein on vesicle endocytosis
was suggested previously (Boassa et al., 2013; Busch et al., 2014)
and demonstrated directly at calyces of Held of prehearing (Xu et
al., 2016) and posthearing (Fig. 1) rats. However, little has been
investigated on the underlying mechanism. We have shown here
that the MT-depolymerizing reagents nocodazole and PST-1,
when loaded into calyceal terminals, completely rescued the in-
hibitory effect of -synuclein on vesicle endocytosis (Fig. 2C–E).
Convincingly, the photo-switchable PST-1 rescued endocytic in-
hibition by -synuclein in a reversible manner (Fig. 2E). These
results strongly suggest that overassembly ofMTs by -synuclein
underlies its toxic effect on endocytosis.
It has been reported that -synuclein assembles tubulins di-
rectly intoMTs in vitro (Alim et al., 2002, 2004). Electron micro-
scopic examination of the reaction products indicates MT
formation by WT--synuclein, whereas A30P and A53T formed
only amorphous aggregates that are distinct from MTs (Alim et
al., 2004). These reports may explain how nocodazole rescues
endocytic inhibition by -synuclein, but not that by A53T in
prehearing rat calyces (Fig. 3C).However, direct assembly ofMTs
by -synuclein in vitro was reported recently to be unreproduc-
ible (Oikawa et al., 2016). Because WT -synuclein promotes
phosphorylation of tau protein by GSK3 (Duka et al., 2009), it
may increase the soluble tau concentration (Ballatore et al.,
2007), thereby promoting new MT assembly. At later stages of
synucleinopathies, aberrant MTs, together with the tubulin ag-
gregates promoted by the-synucleinmutant,may induce traffic
jams in intracellular organelle transport (Ebneth et al., 1998),
thereby causing neuronal degeneration. The detailed mecha-
nisms by which endocytosis is blocked by newly formed MTs
remain to be investigated.
With respect to synaptic functions, presynaptically loaded
-synuclein had no effect on basal transmission at low frequency
or during a short train of repetitive stimulation (Fig. 4A,B). How-
ever, it inhibited exocytosis during prolonged stimulation (Fig. 1D)
and significantly impaired the fidelityofhigh-frequencyneurotrans-
mission (Fig. 4E). These results suggest that the primary target of
-synuclein toxicity is endocytosis. When endocytosis is inhibited
for aprolongedperiod, exocytosis is secondarily impairedbecauseof
a slowing of recycling vesicle replenishment (Fig. 4C; see also Ya-
mashita et al., 2005). This mechanism can explain results from pre-
vious-synucleinoverexpression studies reportingdisruptedvesicle
trafficking (Lee et al., 2006; Scott and Roy, 2012;Wang et al., 2014),
reduced vesicle pool size (Outeiro and Lindquist, 2003; Nemani et
al., 2010; Scott and Roy, 2012), and diminished transmitter release
(Larsen et al., 2006; Nemani et al., 2010; Lundblad et al., 2012;
Janezic et al., 2013). Therefore, even moderate inhibition of vesicle
endocytosis can impair synaptic fidelity during high-frequency neu-
rotransmission, as reported previously for protein kinase G inhibi-
tors (Eguchi et al., 2012). Fast precise neurotransmission is essential
for sensory cognition andmemory formation (Sabatini andRegehr,
1999), as well as formotor coordination (Sugihara et al., 1993). Do-
paminergic neurons, which are involved in PD, express type 3 vesic-
ular glutamate transporters and form glutamatergic synapses that
provide precisely timed signaling (Chuhma et al., 2004). Therefore,
elevated presynaptic -synuclein likely impairs fast neurotransmis-
sion indopaminergic–glutamatergic synapses, therebypossiblygen-
erating early symptoms of synucleinopathies.
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